GNFTF
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -1.52 | $32M | $5M |
| 2025 Q2 | -0.20 | $36M | -$31M |
| 2024 Q4 | -0.58 | $6M | $27M |
| 2024 Q2 | 0.61 | $61M | -$12M |
| 2023 Q4 | -0.16 | $14M | -$31M |
| 2023 Q2 | -0.42 | $11M | -$28M |
| 2022 Q4 | -0.29 | $6M | -$26M |
| 2022 Q2 | -0.21 | $9M | -$49M |